Professional Documents
Culture Documents
New Oral Anticoagulants in Patients With Chronic Kidney Disease
New Oral Anticoagulants in Patients With Chronic Kidney Disease
2 0 1 7;3 7(3):244–252
Brief review
Lara Belmar Vega ∗ , Ángel Luis Martín de Francisco, Jairo Bada da Silva,
Luis Galván Espinoza, Gema Fernández Fresnedo
Servicio de Nefrología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
a r t i c l e i n f o a b s t r a c t
Article history: Patients with chronic kidney disease (CKD) develop bleeding and thrombotic tendencies,
Received 29 March 2016 so the indication of anticoagulation at the onset of atrial fibrillation (AF) is complex. AF
Accepted 29 August 2016 is the most common chronic cardiac arrhythmia, and thromboembolism and ischaemic
Available online 19 May 2017 stroke in particular are major complications. In recent years, new oral anticoagulant drugs
have been developed, and they have shown superiority over the classical AVK in preventing
Keywords: stroke, systemic embolism and bleeding risk, constituting an effective alternative to those
Oral anticoagulants resources.
Atrial fibrillation © 2016 Sociedad Española de Nefrologı́a. Published by Elsevier España, S.L.U. This is an
Chronic kidney disease open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
r e s u m e n
Palabras clave: Los pacientes con enfermedad renal crónica (ERC) tienen tendencias hemorrágicas y trom-
Anticoagulantes orales bóticas, por lo que la indicación de anticoagulación ante la aparición de fibrilación auricular
Fibrilación auricular (FA) es compleja. La FA es la arritmia cardíaca crónica más frecuente, siendo el tromboem-
Enfermedad renal crónica bolismo y el ictus isquémico en particular las complicaciones más importantes. En los
últimos años se han desarrollado nuevos fármacos anticoagulantes orales que han mostrado
superioridad respecto a los clásicos antagonistas de la vitamina K (AVK) en la prevención
de ictus, embolismo sistémico y riesgo de sangrado, constituyendo una alternativa eficaz a
ellos.
© 2016 Sociedad Española de Nefrologı́a. Publicado por Elsevier España, S.L.U. Este es un
artı́culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
夽
Please cite this article as: Belmar Vega L, de Francisco ALM, Bada da Silva J, Galván Espinoza L, Fernández Fresnedo G. Nuevos
anticoagulantes orales en pacientes con enfermedad renal crónica. Nefrologia. 2017;37:244–252.
∗
Corresponding author.
E-mail address: belmarvega@outlook.es (L. Belmar Vega).
2013-2514/© 2016 Sociedad Española de Nefrologı́a. Published by Elsevier España, S.L.U. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
n e f r o l o g i a. 2 0 1 7;3 7(3):244–252 245
Introduction Table 2 – CHA2 DS2 -VASc score for assessing the risk of
stroke in atrial fibrillation.
Patients with chronic kidney disease (CKD) presents a diffi- Factor Points
cult problem in daily clinical practice; these patients have a C Congestive heart failure or LV systolic 1
bleeding tendency due to a primary disorder of haemosta- dysfunction
sis secondary to platelet dysfunction and an abnormality in H Hypertension 1
platelet/subendothelial interaction1 ; the same patients also A2 Age >75 years 2
D Diabetes mellitus 1
had a clotting tendency caused by multiple factors, such
S2 Stroke, TIA or thromboembolism 2
as endothelial damage, increased coagulation factors and
V Vascular disease (previous AMI, 1
decreased fibrinolytic proteins.2 Therefore, tin these patients peripheral artery disease, aortic plaque)
the indication of anticoagulation therapy for atrial fibrillation A Age 65–74 years 1
(AF) is a complex decision, even more so because of the new Sc Women 1
oral anticoagulants that are now available and which are dif-
TIA: transient ischaemic attack; AMI: acute myocardial infarction;
ferent in their renal pharmacokinetics. LV: left ventricle.
The purpose of this article is to clarify decisions concerning Maximum: 9 points. Low risk: 0; intermediate risk: 1; high risk ≥2.
whether to give anticoagulation to CKD patients who develop Source: Camm et al.14
AF, and which anticoagulant drug is best in each case.
Table 4 – Main characteristics of phase III clinical trials on embolism prevention in patients with non-valvular atrial
fibrillation.
RE-LY (dabigatran) ROCKET AF (rivaroxaban) ARISTOTLE + AVERROES ENGAGE AF-TIMI 48
(apixaban) (edoxaban)
® ® ® ®
Trade name Pradaxa Xarelto Eliquis Lixiana
Mechanism of action Factor IIa Factor Xa Factor Xa Factor Xa
Prodrug Yes No No No
EMA authorisation 18/03/2008 30/09/2008 18/05/2011 19/06/2015
Control drug Warfarin (INR 2–3) Warfarin (INR 2–3) Warfarin (INR 2–3) Warfarin (INR 2–3)
Time in the therapeutic TTR 55% TTR 62% (ARISTOTLE) TTR 68.4%
range (TTR) 64% ASA (AVERROES)
Main analysis Non-inferiority Non-inferiority Non-inferiority Non-inferiority
Patients (n) 18,113 14,264 18,201 + 5599 21,105
Age (years) 71.5 73 70/71 70
Follow-up (years) 2 1.9 1.8/1.1 2.1
CHADS (mean) 2.1 3.5 2.1/2.0 2.8
Bioavailability (%) 3–7 66–100 50 62
Tmax (h) 2 2–4 3–4 1–2
Half-life (h) 12–14 5–13 9–14 5.8–10.7
Renal excretion (%) 80 66 25 50
Dialysable Yes No No Ineffective
Indication NVAF + one or more of: NVAF + one or more of: NVAF + one or more of: NVAF + one or more of:
Stroke, TIA or previous Stroke, TIA, chronic heart Stroke, TIA or previous SE Stroke, TIA, chronic
systemic embolism (SE) failure, HTN Heart failure ≥class 2 NYHA heart failure, HTN
Heart failure ≥class 2 NYHA Age ≥75 years Age ≥75 years Age ≥75 years
Age ≥75 years DM, HTN DM, HTN DM, HTN
DM, HTN
Dose 110 mg/12 h (D110) 20 mg/24 h 5 mg/12 h 60 mg/24 h
150 mg/12 h (D150)
Dose adjustment 110 mg/12 h 15 mg/24 h 2.5 mg/12 h (at least 2 30 mg/24 h (at least one
Age >80 years Moderate kidney failure criteria) criterion)
or CrCl 30–50 ml/min (CrCl: 30–49 ml/min) Age ≥80 years Moderate or severe
Treatment with verapamil Severe kidney failure (CrCl Body weight ≤60 kg kidney failure (CrCl:
high risk of GI bleeding 15–29 ml/min) Creatinine ≥1.5 mg/dl 15–50 ml/min)
(133 mol/l) Body weight under
≤60 kg
Concomitant use of
P-glycoprotein (P-gp)
inhibitors: cyclosporine,
dronedarone,
erythromycin or
ketoconazole
Primary efficacy endpoint Stroke/systemic embolism Stroke/systemic embolism Stroke/systemic embolism Stroke/systemic
embolism
Primary safety endpoint Major bleeding Relevant bleeding Major bleeding Major bleeding
Contraindications Hypersensitivity to the Hypersensitivity to the Hypersensitivity to active Hypersensitivity to the
active substance/excipients active substance/excipients substance/excipients active
Patients with severe kidney Clinically significant active Clinically significant active substance/excipients
failure (CrCl <30 ml/min) bleeding bleeding Clinically significant
Clinically significant active Injury or disease, if it poses Liver disease, associated active bleeding
bleeding a significant risk of major with coagulopathy and Liver disease, associated
Injury or disease, if it poses bleeding clinically relevant bleeding with coagulopathy and
a significant risk of major Concomitant treatment risk clinically relevant
bleeding with any other Injury/disease poses a bleeding risk
Concomitant treatment anticoagulant significant risk of major Injury or disease, if it
with any other Liver disease associated bleeding poses a significant risk
anticoagulant with coagulopathy and Concomitant treatment of major bleeding
Liver failure or disease that clinically relevant bleeding with any other Uncontrolled severe
may affect survival risk, including cirrhotic anticoagulant agent hypertension
Concomitant treatment patients with Child-Pugh B Concomitant treatment
with systemic and C with any other
ketoconazole, cyclosporine, Pregnancy and anticoagulant
itraconazole and breast-feeding Pregnancy and
dronedarone breast-feeding
Prosthetic heart valves
require anticoagulant treat
248
Table 5 – Main efficacy and safety results of phase III clinical trials on embolism prevention in patients with non-valvular atrial fibrillation.
RE-LY ROCKET AF ARISTOTLE AVERROES ENGAGEAF-TIMI 48
D110 vs. warfarin % D150 vs. warfarin % Rivaroxaban vs. warfarin Apixaban vs. warfarin % Apixaban vs. ASA % Edoxaban 60 mg/30 mg vs.
patients/year patients/year % patients/year patients/year patients/year warfarin % patients/year
Relative risk (95% CI) Relative risk (95% CI) Hazard ratio (95% CI) Hazard ratio (95% CI) Hazard ratio (95% CI) Hazard ratio (95% CI)
Stroke or systemic 1.11 vs. 1.69%/year 1.53 vs. 1.69%/year 1.7 vs. 2.2%/year 1.27 vs. 1.6%/year 1.6 vs. 3.7%/year 1.2 vs. 1.5%/year
embolism 0.91 (0.74–1.11) 0.66 (0.53–0.82) 0.79 (0.66–0.96) 0.79 (0.66–0.95) 0.45 (0.32–0.62) 0.79 (0.63–0.99)
p < 0.001 p = 0.41 p < 0.001a p = 0.01 p < 0.001 p < 0.001
Intention-to-treat: 2.1 vs. 1.6 vs. 1.5%/year
2.4%/year 1.07 (0.87–1.31)
0.88 (0.75–1.03) p < 0.005
p < 0.001b
Haemorrhagic stroke 0.12 vs. 0.38%/year 0.10 vs. 0.38%/year – 0.24 vs. 0.47%/year 0.2 vs. 0.3%/year 0.26 vs. 0.47%/year
0.31 (0.17–0.56) 0.26 (0.14–0.49) 0.51 (0.35–0.75) 0.67 (0.24–1.88) 0.54 (0.38–0.77)
p < 0.001 p < 0.001 p < 0.001 p = 0.45 p < 0.001
0.16 vs. 0.47%/year
0.33 (0.22–0.50)
n e f r o l o g i a. 2 0 1 7;3 7(3):244–252
p < 0.001
Ischaemic stroke/not 1.34 vs. 1.20%/year 0.92 vs. 1.20%/year – 0.97 vs. 1.05%/year 1.1 vs. 3.0%/yearc 0.87 vs. 0.93%/year
specified 1.11 (0.89–1.40) 0.76 (0.60–0.98) 0.92 (0.74–1.13) 0.37 (0.25–0.55) 0.94 (0.75–1.19)
p = 0.35 p = 0.03 p = 0.42 p < 0.001 p < 0.001
0.3 vs. 0.1%/yeard
2.24 (0.69–7.27)
p = 0.18
Major bleeding 2.71 vs. 3.36%/year 3.11 vs. 3.36%/year 14.9 vs. 14.5%/year 2.13 vs. 3.09%/year 1.4 vs. 1.2%/year 2.75 vs. 3.43%/year
0.80 (0.69–0.93) p = 0.003 0.93 (0.81–1.07) 1.03 (0.96–1.11) 0.69 (0.60–0.80) 1.13 (0.74–1.75) 0.80 (0.71–0.91)
p = 0.31 p = 0.44 p < 0.001 p = 0.57 p < 0.001
1.61 vs. 3.43%/year
0.47 (0.41–0.55)
p < 0.001
Intracranial haemorrhage 0.23 vs. 0.74%/year 0.30 vs. 0.74%/year 0.49 vs. 0.74%/year 0.33 vs. 0.80%/year 0.4 vs. 0.4%/year 0.39 vs. 0.85%/year
0.31 (0.20–0.47) p < 0.001 0.40 (0.27–0.60) p < 0.001 0.67 (0.47–0.93) 0.42 (0.30–0.58) 0.85 (0.38–1.90) 0.47 (0.34–0.63)
p = 0.019 p < 0.001 p = 0.69 p < 0.001
0.26 vs. 0.85%/year
0.30 (0.21–0.43)
p < 0.001
Clinically relevant – – 11.80 vs. 11.37%/year 4.07 vs. 6.01%/year 3.1 vs. 2.7%/year 11.1 vs. 13.0%/year
bleeding 1.04 (0.96–1.13) 0.68 (0.61–0.75) 1.15 (0.86–1.54) 0.86 (0.80–0.92)
p = 0.345 p < 0.001) p = 0.35 p < 0.001
8.0 vs. 13.0%/year
0.62 (0.57–0.67)
p < 0.001
a
Per protocol.
b
Per intention-to-treat.
c
Haemorrhagic.
d
Not specified.
n e f r o l o g i a. 2 0 1 7;3 7(3):244–252 249
Table 6 – Recommended doses of new oral anticoagulants (NOACs) according to glomerular filtration rates.
NOAC Glomerular filtration rate (GFR)
a
A dose reduction to 220 mg (110 mg/12 h) should be considered in patients with a high risk of bleeding.
b
The FDA authorises a dose of 75 mg/12 h for patients with CrCl 15–30 ml/min, based on pharmacokinetic models. The other regulatory agencies
contraindicate dabigatran if CrCl is <30 ml/min.
c
Given the limited clinical data, caution should be exercised in patients with CrCl 15–30 ml/min.
d
A dose reduction of 2.5 mg/12 h is recommended in patients with CrCl 15–30 ml/min and in patients with serum creatinine ≥1.5 mg/dl
(133 mol/l), associated with age ≥80 years or body weight ≤60 kg.
e
A dose reduction to 30 mg/24 h is recommended in patients with one or more of the following clinical factors: CrCl 15–50 ml/min, body weight
under ≤60 kg, concomitant use of the following P-gp inhibitors: cyclosporine, dronedarone, erythromycin or ketoconazole.
and any other type of bleeding were significantly higher with • For GFR between 30 and 50 ml/min, the doses of dabi-
rivaroxaban than with apixaban and D110; as edoxaban 60 mg gatran and rivaroxaban should be reduced (if there is a
vs edoxaban 30 mg. Edoxaban 30 mg showed a significant high risk of bleeding), and it is not necessary to reduce
reduction in major bleeding compared with the other NOACs, the doses of apixaban and edoxaban. For GFR from 15 to
and vs D150, D110 and rivaroxaban. 29 ml/min, dabigatran is contraindicated, dose of rivarox-
With no direct comparative studies among these NOACs, aban and edoxaban do not need to be adjusted, while
the selection of one or the other must depend on the apixaban does. None of the NOACs is indicated for GFR
physician’s view of the benefit in each study. The specific below 15 ml/min.
recommendations accepted by the regulatory agencies and, • There is currently a specific reversal agent for dabigatran,
above all, the (necessary) economic constraints imposed by indicated in patients requiring surgery or with severe bleed-
the different funding agencies, including patients’ purchas- ing. For the rest of the NOACs, new specific reversal agents
ing power. A recent systematic review of 23 studies by Ferreira are expected soon.
and Mirco44 concluded that NOACs are beneficial in preventing • NOACs are more expensive than VKAs. However, their cost
stroke in AF, and, without analysing edoxaban, given its very tends to decrease as new drugs come on the market. How-
recent approval, it seems that apixaban is the most reward- ever, the lower risk of thromboembolic events and bleeding
ing, followed by dabigatran and rivaroxaban. However, given provides a cost-effective alternative compared with VKAs.
the limitations of the different analytical models used, and
until further studies are performed, these results should be
considered with caution. Conflicts of interest
Key concepts
references
6. Expósito V, Seras M, Fernández-Fresnedo G. Oral 23. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.
anticoagulation in chronic kidney disease with atrial Meta-analysis of efficacy and safety of new oral
fibrillation. Med Clin (Barc). 2015;144:452–6. anticoagulants (dabigatran, rivaroxaban, apixaban) versus
7. Belmar L, de Francisco AL, Bueno L, Piñera C, Monfá E, warfarin in patients with atrial fibrillation. Am J Cardiol.
Kislikova M, et al. Ictus en pacientes en hemodiálisis: 2012;110:453–60.
incidencia, tiempo de aparición y factores asociados. 24. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu
Nefrologia. 2014;34:347–52. N, Ezekowitz MD, et al. Comparison of the efficacy and safety
8. Murray AM, Seliger S, Lakshminarayan K, Herzog CA, Solid of new oral anticoagulants with warfarin in patients with
CA. Incidence of stroke before and after dialysis initiation in atrial fibrillation: a meta-analysis of randomised trials.
older patients. J Am Soc Nephrol. 2013;24:1166–73. Lancet. 2014;383:955–62.
9. Eckardt KU, Gillespie IA, Kronenberg F, Richards S, Stenvinkel 25. Morimoto T, Crawford B, Wada K, Ueda S. Comparative
P, Anker SD, et al., ARO Steering Committee. High efficacy and safety of novel oral anticoagulants in patients
cardiovascular event rates occur within the first weeks of with atrial fibrillation: a network meta-analysis with the
starting hemodialysis. Kidney Int. 2015;88:1117–25. adjustment for the possible bias from open label studies. J
10. U.S. Renal Data System. USRDS 2006 Annual Data Report: Cardiol. 2015;66:466–74.
Atlas of End-Stage Renal Disease in the United States. 26. Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster
Bethesda, MD: National Institutes of Health, National JY, et al. Dabigatran etexilate and risk of myocardial
Institute of Diabetes and Digestive and Kidney Diseases; 2006. infarction, other cardiovascular events, major bleeding, and
11. Vázquez E, Sánchez-Perales C, Lozano C, García-Cortés MJ, all-cause mortality: a systematic review and meta-analysis of
Borrego F, Guzmán M, et al. Comparison of prognostic value randomized controlled trials. J Am Heart Assoc.
of atrial fibrillation versus sinus rhythm in patients on 2014;3:e000515.
long-term hemodialysis. Am J Cardiol. 2003;92:868–71. 27. U.S. Food and Drug Administration. Available from:
12. Findlay MD, Thomson PC, Fulton RL, Solbu MD, Jardine AG, http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm
Patel RK, et al. Risk factors of ischemic stroke and subsequent [accessed 14.05.16].
outcome in patients receiving hemodialysis. Stroke. 28. Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ,
2015;46:2477–81. Marchlinski FE. Meta-analysis of gender differences in
13. January CT, Wann L, Alpert JS, Calkins H, Cigarroa JE, residual stroke risk and major bleeding in patients with
Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the nonvalvular atrial fibrillation treated with oral
management of patients with atrial fibrillation: executive anticoagulants. Am J Cardiol. 2014;113:
summary: a report of the American College of 485–90.
Cardiology/American Heart Association Task Force on 29. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA,
Practice Guidelines and the Heart Rhythm Society. J Am Coll Yang S, et al., for the RE-LY Study Group. Dabigatran
Cardiol. 2014;64:2246–80. compared with warfarin in patients with atrial fibrillation
14. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, and previous transient ischaemic attack or stroke: a subgroup
et al., European Heart Rhythm Association; European analysis of the RE-LY trial. Lancet Neurol. 2010;9:
Association for Cardio-Thoracic Surgery. Guidelines for the 1157–63.
management of atrial fibrillation: the task force for the 30. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G,
management of atrial fibrillation of the European Society of Carolei A, et al., ROCKET AF Steering. Rivaroxaban compared
Cardiology (ESC). Eur Heart J. 2010;31:2369–429. with warfarin in patients with atrial fibrillation and previous
15. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A stroke or transient ischaemic attack: a subgroup analysis of
novel user-friendly score (HAS-BLED) to assess 1-year risk of ROCKET AF. Lancet Neurol. 2012;11:315–22.
major bleeding in patients with atrial fibrillation: the Euro 31. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB,
Heart Survey. Chest. 2010;138:1093–100. Wallentin L, et al., ARISTOTLE Committees and Investigators.
16. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Apixaban compared with warfarin in patients with atrial
Bernstein RA, et al. Idarucizumab for dabigatran reversal. N fibrillation and previous stroke or transient ischaemic attack:
Engl J Med. 2015;373:511–20. a subgroup analysis of the ARISTOTLE trial. Lancet Neurol.
17. Wittkowsky AK. Novel oral anticoagulants and their role in 2012;11:503–11.
clinical practice. Pharmacotherapy. 2011;31:1175–91. 32. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus
18. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, aspirin for preventing stroke in patients with atrial
Parekh A, et al., for the RE-LY Steering Committee and fibrillation. Ann Intern Med. 2007;147:590–2.
Investigators. Dabigatran versus warfarin in patients with 33. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G,
atrial fibrillation. N Engl J Med. 2009;361:1139–51. American College of Chest Physicians. Pharmacology and
19. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, management of the vitamin K antagonists: American College
et al., for the ROCKET AF Investigators. Rivaroxaban versus of Chest Physicians Evidence-Based Clinical Practice
warfarin in nonvalvular atrial fibrillation. N Engl J Med. Guidelines (8th Edition). Chest. 2008;133 Suppl.:
2011;365:883–91. 160S–98S.
20. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, 34. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP.
Hanna M, et al., for the ARISTOTLE Committees and Risks of stroke and mortality associated with suboptimal
Investigators. Apixaban versus warfarin in patients with anticoagulation in atrial fibrillation patients. Thromb
atrial fibrillation. N Engl J Med. 2011;365:981–92. Haemost. 2011;106:968–77.
21. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn 35. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke
S, et al., for the AVERROES Steering Committee and in patients with non-valvular atrial fibrillation and no
Investigators. Apixaban in patients with atrial fibrillation. N previous history of stroke or transient ischemic attacks.
Engl J Med. 2011;364:806–17. Cochrane Database Syst Rev. 2005:CD001927.
22. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, 36. Koudstaal PJ. Anticoagulants versus antiplatelet therapy for
Halperin JL, et al., ENGAGE AF-TIMI 48 Investigators. preventing stroke in patients with nonrheumatic atrial
Edoxaban versus warfarin in patients with atrial fibrillation. fibrillation and a history of stroke or transient ischemic
N Engl J Med. 2013;369:2093–104. attacks. Cochrane Database Syst Rev. 2000:CD000187.
252 n e f r o l o g i a. 2 0 1 7;3 7(3):244–252
37. Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, 41. Krüger T, Brandenburg V, Schlieper G, Marx N, Floege J. Sailing
et al. Stroke and bleeding in atrial fibrillation with chronic between Scylla and Charybdis: oral long-term anticoagulation
kidney disease. N Engl J Med. 2012;367:625–35. in dialysis patients. Nephrol Dial Transplant. 2013;28:534–41.
38. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use 42. Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.
associates with increased risk for stroke in hemodialysis Comparative efficacy and safety of new oral anticoagulants in
patients with atrial fibrillation. J Am Soc Nephrol. patients with atrial fibrillation. Circ Cardiovasc Qual
2009;20:2223–33. Outcomes. 2012;5:480–6.
39. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell 43. Fu W, Guo H, Guo J, Lin K, Wang H, Zhang Y, et al. Relative
RB, et al. Atrial fibrillation in hemodialysis patients: clinical efficacy and safety of direct oral anticoagulants in patients
features and associations with anticoagulant therapy. Kidney with atrial fibrillation by network meta-analysis. J Cardiovasc
Int. 2010;77:1098–106. Med (Hagerstown). 2014;15:873–9.
40. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. 44. Ferreira J, Mirco A. Systematic review of cost-effectiveness
Effectiveness and safety of warfarin initiation in older analyses of novel oral anticoagulants for stroke prevention in
hemodialysis patients with incident atrial fibrillation. Clin J atrial fibrillation. Rev Port Cardiol. 2015;34:179–91.
Am Soc Nephrol. 2011;6:2662–8.